Search Results
98 Results Found for “neoplasms”
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
Early-onset lung cancer is typically defined as occurring in individuals aged 18–50 years, although there is no universally accepted definition.1–3 This entity, though rare, poses unique diagnostic and therapeutic challenges. This article synthesizes current evidence on the unique features and management ...
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1Â Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2Â Head and neck squamous cell carcinoma (...
Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms. In this episode, we speak with Prof. John Mascarenhas, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
Key points Olutasidenib induces durable responses in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations in the phase I and II clinical trials. The side effects of olutasidenib are well known and ...
To date, the cornerstone of curative treatment in early-stage gastrointestinal (GI) cancers includes surgery and sometimes radiation therapy. Depending on the stage and tumour type, these approaches are often combined with systemic neoadjuvant or adjuvant therapies. After all definitive therapy ...
Neuroendocrine neoplasms (NENs) comprise a heterogenous group of malignancies with diverse clinical behaviour determined by tumour characteristics such as grade, differentiation and primary tumour origin.1 While neuroendocrine carcinomas are poorly differentiated aggressive malignancies, well-differentiated neuroendocrine tumours (NETs) tend to be ...
Somatic DNA mutational analysis has transformed how we characterize existing cancer and select treatments. For example, circulating tumour cell-free DNA (cfDNA) can be used to select targeted therapies, monitor treatment response and detect disease recurrence.1Â However, early attempts with targeted ...
Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1Â Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In ...
Myelodysplastic syndromes (MDS) are a group of clonal myeloid neoplasms characterised by blood cytopaenia, cellular dysplasia and predisposition to the development of acute myeloid leukaemia (AML).1,2 MDS are common in older individuals, with an incidence that varies from 2–12/100,000 inhabitants/year ...
An ever-expanding understanding of the biological basis for multiple myeloma (MM) combined with a widening array of effective therapies has dramatically improved outcomes for patients and has provided new opportunities for disease segmentation and targeted therapeutics.1Â While this progress is ...
At the 61st ASH Annual Meeting & Exposition, Srdan Verstovsek, Anderson Cancer Center, discusses his presentation on Approaches to the Individualized Management of Myeloproliferative Neoplasms: Best Practices and Guidance to Optimize Care. Questions 1. What impact has molecular profiling had on ...
At the 61st ASH Annual Meeting & Exposition, Abdulraheem Yacoub, University of Kansas Medical Center, discusses his presentation: MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis. Questions 1. What are the most exciting recent ...
At the 61st ASH Annual Meeting & Exposition, Raajit Rampal, Memorial Sloan Kettering Cancer Center, discusses his presentation: Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care. Questions 1. Given the variable nature of myeloproliferative neoplasms (...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
